🔎 Trials Near Me

Home › Esophageal Adenocarcinoma › Indiana

Pag-aaral pangklinika para sa Esophageal Adenocarcinoma sa Indiana

6 pag-aaral para sa Esophageal Adenocarcinoma ang naghahanap ng mga kalahok sa mga site sa Indiana.

Mga Lungsod sa Indiana

Opisyal na teksto ng pag-aaral (English)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Northwest Cancer Center - Crown Point, Crown Point
  • Northwest Oncology LLC, Dyer
  • Northwest Cancer Center - Hobart, Hobart
  • at 5 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • Northwest Cancer Center - Crown Point, Crown Point
  • UChicago Medicine Northwest Indiana, Crown Point
  • Northwest Oncology LLC, Dyer
  • at 6 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05677490

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Community Health Network, Indianapolis
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06324357

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

  • Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
Nagre-recruit
Edad 18 hanggang 89 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05753748

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • UChicago Medicine - Northwest Indiana, Crown Point
  • Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
  • Community Health Network, Inc, Indianapolis
  • at 3 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04389632

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.